Some works have shown that therapies focusing on the interaction between SARS-CoV-1 and the ACE2 receptor may be extended for use in SARS-CoV-2 patients as an immunotherapy tool (218). However, other authors refute this idea based on the fact that recent studies showed limited cross-neutralization between SARS-CoV-1 antibodies and SARS-CoV-2 (280, 281). Furthermore, it was shown that SARS-CoV-2 S protein binds ACE2 with a higher affinity than SARS-CoV-1, suggesting that such interaction differs between the two viruses (266).